Device Trial Radar · NCT03505567
Study to Compare Kowa OCT Bi-μ and the Optovue iVue 100
Last checked: Nov 19, 2026Latest source record: Sep 10, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Apr 21, 2018
Primary completion
Sep 1, 2018
Study completion Sep 1, 2018
Sponsor
- Lead sponsor
- Kowa Research Institute, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 23, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a prospective comparative study to gather pilot agreement and precision data in normal subjects, subjects with glaucoma, and subjects with retinal disease.
Conditions
- Glaucoma
- Retinal Disease
- Healthy
Interventions
KOWA OCT Bi-µDevice
Non-contact, ultra-high resolution ophthalmic imaging system for fundus imaging and axial cross-sectional and three-dimensional imaging of retinal structures.
Optovue iVue 100Device
U.S. Food and Drug Administration (FDA) cleared and commercially available Optovue iVue 100
Primary outcomes
What the sponsor says the trial is designed to measure.
- Compare KOWA OCT Bi-μ and Optovue iVue 100Time frame: 1-2 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Andover Eye Associates
Andover, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.